XGN EXAGEN INC.
Services-Medical Laboratories · Nasdaq · SEC CIK 1274737 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.7%
TTM net income YoY4.6%
TTM EPS YoY18.3%
Revenue 3-yr CAGR11.9%
Net income 3-yr CAGR—
Margins
Gross margin58.7%
Operating margin-20.1%
Net margin-25.1%
FCF margin-18.0%
EBITDA margin-16.6%
Returns
ROE-113.9%
ROA-30.8%
ROIC (approx.)-167.2%
Asset turnover1.22x
Leverage & solvency
Liabilities / assets75.1%
Debt / equity1.66x
Current ratio3.46x
Interest coverage-2.90x
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-10.4%
Payout ratio—
Capex / revenue1.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $66.58M | $55.64M |
| Cost of revenue | $27.78M | $22.53M |
| Gross profit | $38.80M | $33.11M |
| R&D expense | $6.25M | $5.38M |
| SG&A expense | $46.62M | $41.37M |
| Operating income | -$14.07M | -$13.64M |
| Interest expense | $4.32M | $2.23M |
| Income tax | $51,000 | $12,000 |
| Net income | -$19.95M | -$15.12M |
| EBITDA | -$11.97M | -$11.94M |
| EPS (basic) | -0.93 | -0.83 |
| EPS (diluted) | -0.93 | -0.83 |
| Weighted avg. shares (diluted) | 21.56M | 18.20M |
| Balance sheet | ||
| Cash & equivalents | $32.22M | $22.24M |
| Receivables | $10.86M | $7.83M |
| Current assets | $48.89M | $36.45M |
| PP&E, net | $6.94M | $5.28M |
| Total assets | $58.02M | $44.69M |
| Current liabilities | $14.16M | $13.51M |
| Short-term debt | $643,000 | $423,000 |
| Long-term debt | $22.26M | $19.82M |
| Total debt | $22.91M | $20.25M |
| Total liabilities | $40.57M | $35.15M |
| Shareholders' equity | $17.45M | $9.54M |
| Net debt | -$9.31M | -$1.99M |
| Shares outstanding | 22.91M | 17.64M |
| Cash flow statement | ||
| Operating cash flow | -$13.62M | -$13.28M |
| Capital expenditure | $641,000 | $515,000 |
| Free cash flow | -$14.27M | -$13.79M |
| Investing cash flow | -$626,000 | -$515,000 |
| Financing cash flow | $24.43M | -$663,000 |
| Depreciation & amortization | $2.10M | $1.70M |
| Stock-based compensation | $2.16M | $1.76M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.